# OnCo record paper-eribulin-liposarcoma-schoffski-lancet-2016 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-eribulin-liposarcoma-schoffski-lancet-2016/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-eribulin-liposarcoma-schoffski-lancet-2016" ;
  schema:name "Eribulin versus dacarbazine in previously treated advanced liposarcoma or leiomyosarcoma"@en ;
  schema:description "Eribulin lengthened survival by two months compared with dacarbazine in previously treated liposarcoma and leiomyosarcoma, with the entire benefit in liposarcoma, where survival improved by seven months, leading to its approval for that subtype."@en ;
  schema:url <https://onco.cc/key-papers/paper-eribulin-liposarcoma-schoffski-lancet-2016/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(15)01283-0>, <https://pubmed.ncbi.nlm.nih.gov/26874885/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(15)01283-0> ;
  schema:datePublished "2016"^^xsd:gYear ;
  schema:author "Schöffski P, Chawla S, Maki RG, et al." ;
  onco:cancers <https://onco.cc/cancers/liposarcoma/> ;
  onco:drugs <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/drugs/eribulin/> ;
  onco:journals <https://onco.cc/journals/lancet/> .